SIGLEC15 and glioma: Furthermore, We report here in for the first time that Siglec15 is upregulated and associated with clinicopathological features such as ageing, higher WHO grade, IDH wildtype, 1p/19q non-coding, reduced PFST and OST, and infiltrating immunosuppressive cells in gliomas.